• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

lyndra

Lyndra Therapeutics touts Phase 2 data for oral schizophrenia treatment

April 19, 2021 By Sean Whooley

lyndra-therapeutics-logo

Lyndra Therapeutics yesterday announced positive results from a Phase 2 study of its once-weekly, oral schizophrenia treatment. Watertown, Mass.-based Lyndra’s oral, long-acting, extended-release risperidone capsule, LYN-005, is designed for the weekly treatment of schizophrenia. Data from the company’s first repeat-dose Phase 2 study demonstrate that LYN-005 offered sustained therapeutic levels of risperidone over the one-week […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: lyndra

Lyndra Therapeutics appoints Jenkins, Fernandes to executive roles

March 31, 2021 By Sean Whooley

lyndra-therapeutics-logo

Lyndra Therapeutics announced today that it appointed Abigail Jenkins and Jacqueline Fernandes to executive positions at the company. Jenkins will take over as chief commercial & business officer, while Fernandes assumes the role of VP of data compliance and information technology at the Watertown, Mass.-based developer of oral, long-acting, sustained-release therapeutics. “We are pleased to […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: lyndra, Personnel, Personnel Moves

Lyndra to develop ultra-long-acting opioid use disorder therapy

April 9, 2019 By Danielle Kirsh

lyndra-therapeutics-logo

Lyndra Therapeutics (Watertown, Mass.) announced that it is developing an ultra-long-acting oral treatment for opioid use disorder. On average, about 130 Americans die every day from an opioid overdose, according to the Centers for Disease Control and Prevention. Lyndra Therapeutics received a grant from the National Institutes of Health to help find new treatment strategies […]

Filed Under: Pain Management Tagged With: lyndra

Lyndra raises $55m for long-acting drug delivery capsule

January 29, 2019 By Sarah Faulkner

Lyndra updated

Lyndra Therapeutics said today that it raised $55 million in a Series B round to support the development of its oral drug delivery system. All of the investors from the company’s $23 million Series A round resubscribed for the Series B round, Lyndra reported. New investors included the Bill & Melinda Gates Foundation. Lyndra’s oral […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: lyndra

Lyndra touts positive results for long-acting drug-delivery tech

November 15, 2018 By Sarah Faulkner

Lyndra updated

Lyndra Therapeutics reported positive results from a pharmacokinetics study of its once-weekly drug-delivery capsule, touting that it successfully transitioned a once-daily therapy to a weekly dosage form. The Watertown, Mass.-based company’s oral drug-delivery technique is designed to provide sustained release of one or more drugs for up to a week. Lyndra’s star-shaped capsule opens when […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: lyndra

Researchers develop capsule to deliver a week’s worth of HIV drugs

January 24, 2018 By Sarah Faulkner

weekly HIV drug

A team of researchers from the Massachusetts Institute of Technology and Brigham & Women’s Hospital have developed a drug-delivery capsule that can deliver a week’s worth of HIV drugs in a single dose. The technology is designed to make it easier for people with HIV to deal with the strict schedule of medications they need […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, lyndra, Massachusetts Institute of Technology

Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017

September 14, 2017 By Sarah Faulkner

Ocular Therapeutix

After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aeterna Zentaris, Bayer AG, Biogen Idec, Eyevensys, lyndra, Mylan, Ocular Therapeutix, Proteus Digital Health, rebiotix, Teva

Lyndra lands $105m deal with Allergan for once-weekly Alzheimer’s drugs

September 8, 2017 By Sarah Faulkner

Lyndra

Boston-based startup Lyndra said today that it is partnering with pharma giant Allergan (NYSE:AGN) to develop orally administered, once-weekly products for the treatment of Alzheimer’s disease. The collaboration will combine Allergan’s proprietary Alzheimer’s drugs with Lyndra’s sustained-release technology, which is designed to temporarily reside in the stomach for up to one week while delivering a drug. […]

Filed Under: Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, lyndra

Powering the next generation of ingestible drug delivery devices

May 17, 2017 By Sarah Faulkner

Traditional implants in the gastrointestinal tract are meant to pass through a patient’s system, delivering a drug in short bursts or recording the health of a patient’s colon. But in recent years, scientists have sought after ultra-long lasting ingestible devices that can deliver drugs for several weeks in a patient’s GI tract. Lyndra, Inc., a start-up […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Draper, lyndra, Massachusetts Institute of Technology

Lyndra gets boost for drug delivery platform from U.S. allergy institute

May 2, 2017 By Sarah Faulkner

Lyndra

Lyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the formulation and preclinical development of a once-weekly oral HIV treatment. The Watertown, Mass.-based company makes use of a sustained-release technology developed by Robert […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Research & Development Tagged With: lyndra, Massachusetts Institute of Technology, National Institutes of Health

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS